For informational purposes only — not investment advice

← Back to signals

ORIC

INSIDER SELL

Oric Pharmaceuticals, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
4.8d↓-34.2%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Positive

ORIC demonstrated strong clinical progress with enozimetostat showing best-in-class lung cancer efficacy (84% systemic ORR, 88% 6-month PFS) and rinzimetostat providing differentiated prostate cancer data, supported by robust cash runway (~$345M extending into H2 2028). However, a late-October stock selloff tied to competitive J&J prostate cancer data created near-term volatility, though analyst consensus remains supportive with multiple Buy ratings and price targets ranging $14–$26.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Piscitelli DominicChief Financial OfficerSELL14K$13.53$0.19M2026-10-20↗
Heyman Richard A.—SELL4K$12.91$0.05M2026-10-01↗
Heyman Richard A.—SELL3K$12.91$0.04M2026-10-01↗

Fund 13D/13G Filings (3)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Viking GlobalSC 13G/A−2.3M5.7%
+5.6% vs SPY
+2.4% abs
2026-11-16↗
Point72SC 13G/A—0.0%
+62.8% vs SPY
+68.3% abs
2026-05-15↗
Viking GlobalSC 13G/A—7.8%
+62.8% vs SPY
+68.3% abs
2026-05-15↗